Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 FOLFIRINOX in previously untreated metastatic pancreatic cancer
jRCT2080221426Phase 2
- Sponsor
- Yakult Honsha
- Start
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of FOLFIRINOX in pancreatic adenocarcinoma (PDAC), pancreatic adenosquamous carcinoma (PASC) and pancreatic cancer (PC), sponsored by Yakult Honsha.
02
Drugs
FOLFIRINOX
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic adenosquamous carcinoma (PASC)pancreatic cancer (PC)
Beyond the preview
Go deeper on jRCT2080221426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221426.